Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.
Attributes | Values |
---|
type
| |
sameAs
| |
wasDerivedFrom
| |
dbpedia-owl:abstract
| - Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.
- Amarin Corporation ist ein irisch-amerikanischer Pharmakonzern mit Sitz in Dublin und Bridgewater. Das im Jahr 1993 gegründete Unternehmen ist auf die Herstellung und Vermarktung von Medikamenten zur Behandlung von Herz-Kreislauf-Erkrankungen spezialisiert und brachte mit Vascepa (US) 2013 ein entsprechendes Präparat auf den nordamerikanischen Markt.
|
dbpedia-owl:thumbnail
| |
dbpedia-owl:type
| |
dbpedia-owl:wikiPageExternalLink
| |
dbpedia-owl:wikiPageID
| |
dbpedia-owl:wikiPageRevisionID
| |
comment
| - Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.
- Amarin Corporation ist ein irisch-amerikanischer Pharmakonzern mit Sitz in Dublin und Bridgewater. Das im Jahr 1993 gegründete Unternehmen ist auf die Herstellung und Vermarktung von Medikamenten zur Behandlung von Herz-Kreislauf-Erkrankungen spezialisiert und brachte mit Vascepa (US) 2013 ein entsprechendes Präparat auf den nordamerikanischen Markt.
|
label
| - Amarin
- Amarin Corporation
|
dbpprop:wikiPageUsesTemplate
| |
name
| |
dbpprop:numEmployees
| |
described by
| |
topic
| |
name
| |
depiction
| |
homepage
| |
dbpprop:products
| |
http://purl.org/li...ics/gold/hypernym
| |
location
| |
dbpprop:location
| |
dbpprop:type
| |
Subject
| |
is primary topic of
| |
has close match
| |
dbpedia-owl:foundingYear
| |
dbpprop:logo
| |
dbpprop:revenue
| |
dbpedia-owl:wikiPageLength
| |
dbpedia-owl:wikiPageWikiLink
| |